Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

Daiichi Sankyo has announced the first subject dosing in the Phase III DESTINYEndometrial01 trial of Enhertu (trastuzumab ...

Merck & Co Inc. (MRK) and Daiichi Sankyo on Thursday said that the companies have withdrawn their application to the U.S.

The cancer drug Enhertu stalled the growth of tumors by well over a year in a group of women with a type of metastatic but ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic non-small cell lung cancer with EGFR mutations.

Merck (NYSE:MRK) and Daiichi Sankyo (OTCPK:DSNKY) (OTCPK:DSKYF) announced Thursday the voluntary withdrawal of their U.S. marketing application targeted at the FDA’s accelerated approval of the lung ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Looking for a new opportunity in New Jersey? These nine companies have open roles that could be a great fit for you.

Rahway: Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, have announced that the Biologics ...

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...